849758-12-9

Basic information

• Product Name: METHYL 4-BROMO-3-FLUOROBENZOATE 98
• Synonyms: METHYL 4-BROMO-3-FLUOROBENZOATE 98;Methyl 4-bromo-3-fluorobenzoate 98%;Benzoicacid, 4-broMo-3-fluoro-, Methyl ester;Bromo-3-fluorobenzoate
• CAS NO: 849758-12-9
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.0354
• Product Categories: blocks;Bromides;Carboxes;Fluorine series
• Mol File: 849758-12-9.mol
• Article Data: 19

Chemical Properties

• Melting Point: 64-66
• Boiling Point: 270.079 °C at 760 mmHg
• Flash Point: 117.14 °C
• Appearance: /
• Density: 1.578 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: Keep Cold
• Solubility: soluble in Methanol
• CAS DataBase Reference: METHYL 4-BROMO-3-FLUOROBENZOATE 98(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-BROMO-3-FLUOROBENZOATE 98(849758-12-9)
• EPA Substance Registry System: METHYL 4-BROMO-3-FLUOROBENZOATE 98(849758-12-9)

Safety Data

• Hazard Codes: Xi
• RIDADR: 2811
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 849758-12-9(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

InChI:InChI=1/C8H6BrFO2/c1-12-8(11)5-2-3-6(9)7(10)4-5/h2-4H,1H3

Upstream product

• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 403-01-0 methyl 3-fluoro-4-hydroxybenzoate 
• 948840-10-6 methyl 4-[(1E)-3-tert-butoxy-3-oxoprop-1-en-1-yl]-3-fluorobenzoate 
• 849757-74-0 3-fluoro-4-(3-trifluoromethylpyridin-2-yl)-benzoic acid 
• 849757-89-7 4-(3-chloropyridin-2-yl)-3-fluorobenzoic acid 
• 849757-78-4 4-(3-methoxypyridin-2-yl)-3-fluorobenzoic acid 
• 1093061-56-3 C₃₆H₃₆F₂N₈O₄ 
• 1093064-31-3 4-[4-(5-ethylamino-[1,3,4]oxadiazol-2-yl)-2-fluoro-phenyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1093064-35-7 2-chloro-1-{4-[4-(5-ethylamino-[1,3,4]oxadiazol-2-yl)-2-fluoro-phenyl]-3,6-dihydro-2H-pyridin-1-yl}-ethanone 
• 1093064-68-6 4-[2-fluoro-4-(5-methyl-[1,3,4]oxadiazol-2-yl)-phenyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1093064-33-5 ethyl-{5-[3-fluoro-4-(1,2,3,6-tetrahydro-pyridin-4-yl)]-[1,3,4]oxadiazol-2yl}-amine 
• 1093064-29-9 [5-(4-bromo-3-fluoro-phenyl)-[1,3,4]oxadiazol-2-yl]-ethyl-amine 
• 948840-11-7 methyl 4-(3-tert-butoxy-3-oxopropyl)-3-fluorobenzoate 
• 948840-09-3 3-[2-fluoro-4-(methoxycarbonyl)phenyl]propanoic acid 

Relevant articles and documents

Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria

Herein, we describe the discovery and optimization of a novel series that inhibits bacterial DNA gyrase and topoisomerase IV via binding to, and stabilization of, DNA cleavage complexes. Optimization of this series led to the identification of compound 25

SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION

The present invention relates to compounds of formula I: in which A1-A7 and R1 to R5 are defined herein, for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). The invention also relates to pharmaceutical compounds comprising such compounds, and related methods of treatment. In an aspect, the invention relates to a method of screening compounds for therapeutic potential in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). Aspects of the invention relate to novel compounds of formula I in which at least one of A1 to A3 is N or at least one of A4 is CR12 or A5 is CR13 in which R12/R13 is halogen.

NOVEL AROMATIC COMPOUND AND USE THEREOF

Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.